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Abstract
The homovanillic acid (HVA) concentrations in the lumbar cerebrospinal ﬂuid (CSF) were
determined in 38 epileptic and 39 control patients. The mean concentration of HVA was 23.9
ng/ml +/- 2.8 SEM for the epileptic group and 30.2 ng/ml +/- 2.1 SEM for the control group,
respectively. Thus, HVA was signiﬁcandly reduced in the patients with epilepsy compared with
the controls. The mean HVA in the female patients was higher than in the male patients in both
groups but this failed to reach statistical signiﬁcance. There was no apparent relationship between
the degree of reduced HVA concentration and other clinical indexes of the epilepsy (age, type
and frequency of seizures, and anticonvulsant medication). For the determination of concentration
gradient of HVA three fractions of the spinal CSF were obtained from 11 patients. A pronounced
gradient of HVA concentration was found with a ratio of 1 : 1.46 : 1.97 for the ﬁrst, second
and third fractions. This suggests that a standardized conditions for collecting CSF should be
employed to study HVA levels in humans.
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Abstract. The homovanillic acid (HVA) concentrations in the lum-
bar cerebrospinal fluid (CSF) were determined in 38 epileptic and 39
control patients. The mean concentration of HVA was 23.9 ngjml± 2.8
SEM for the epileptic group and 30.2 ngjml± 2.1 SEM for the control
group, respectively. Thus, HVA was significantly reduced in the pa-
tients with epilepsy compared with the controls. The mean HVA in
the female patients was higher than in the male patients in both groups
but this failed to reach statistical significance. There was no apparent
relationship between the degree of reduced HVA concentration and
other clinical indexes of the epilepsy (age, type and fTequency of sei-
zures, and anticonvulsant medication). For the determination of con-
centration gradient of HVA three fractions of the spinal CSF were
obtained from 11 patients. A pronounced gradient of HVA concentra-
tion was found with a ratio of 1: 1.46: 1.97 for the first, second and
third fractions. This suggests that a standardized conditions for collect-
ing CSF should be employed to study HVA levels in humans.
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An increasing number of reports on the cerebrospinal fluid (CSF) concent-
rationof homovanillic acid (HVA), the major metabolite ofdopamine, have been
appearing in recent literature. The reason for measuring the concentration of
BVA in clinical studies can be judged from the following evidence concerning
the origin of HVA in the CSF. The BVA concentration in animal and human
lumbarCSF reflects the metabolism ofdopamine in the brainbut not inthespinal
cord (1-3). HVA derived from neural structures adjacent to the lateral ventri-
cles, mainly the caudate nucleus, is transported from the lateral ventricles
through the third and fourth ventricles to the spinal subarachnoid space by diffu-
sion and CSF flow (4,5), and is removed from CSF to the blood by an active
transport mechanism (6). When humans are given et
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the cisternal CSF reaches a maximumafter 2-4 h, but does not attain its maxi-
mum concentration in the lumbar CSF until 8 h (7). Peripherally administered
HVA does not penetrate appreciably into the CSF (8). Thus, HVA concentra-
tion in animal and humanCSF decreases from the ventricular through the cister-
nal to the lumbar compartments (I, 6, 9, I0). Thecompartmental ratio of HVA
inhumans is approximately9: 4.5: I for the ventricular, the cisternal and the
lumbar CSF, respectively (3). This evidence suggests that HVA concentration in
human lumbar CSF could provide important information on the dopaminergic
neuronal activity in the brain, mainly the nigro-striatal system.
The present communication deals with HVA concentration in the lumbar
CSF of patients with epilepsy. In addition, CSF from different levels in the
spinal subarachnoid system was analysed in order to assess the concentration
gradient ofHVA.
MATERIALS AND METHODS
In order to determine the gradient of HVA concentration three fractions of
the spinal CSF were obtained from 11 patients during diagnostic pneumoence-
phalography (PEG). Preparatory medication was given intramuscularly 30 min
before PEG was started. In most cases this consisted of atropine sulfate (0.2-0.5
mg) and hydroxyzine hydrochloride (1 mg/kg). The procedures were performed
after intramuscular injection of ketamine hydrochloride (5 mg/kg) in the patients
under 7 years of age. Patients with evidence of obstruction of CSF flow were
excluded from this series. After the lumba, puncture had been performed while
seated, the initial 5-6ml of CSF was taken for the first sample (fraction I) and the
same volume of room air was injected through the puncture needle. This pro-
cedure was then repeated twice for the second and third samples (fractions II and
III).
HVA concentration in the lumbar CSF was determined in 38 epileptic and
39 various neurological or psychiatric patients. The patients with epilepsy were
18 males and 20 females ranging in age from 5 months to 55 years, with a mean of
21.4 years. They consisted of 6 patients with Lennox-Gastaut syndrome (child-
hood epileptic encephalopathy with diffuse slow spike-waves), one with atonic
seizures, one with tonic, 15 with generalized tonic-clonic, one with psychomotor
in addition to generalized, 6 with psychomotor, one with autonomic, 2 with ad-
versive and 5 with focal cortical seizures. Seizure frequency of these patients
varied from once a year to over 10 times per day. While five patients were
studied before anticonvulsant medication was initiated, the remaining 33 patients
were receiving various anticonvulsant drugs such as diphenylhydantoin, pheno-
barbital, or carbamazepine either alone or in various combinations at the time of
the study. On the other hand, because of difficulty in obtaining CSF from the
normal subjects, those patients comprising the control group in this study had
various central nervous system disorders excluding epilepsy, extrapyramidal
diseases and hydrocephalus. Patients with paroxysmal discharges on the e1ectro-
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encephalogramswere also excluded from the control group. They were 25 males
and 14 females ranging in age from one to 71 years, with a mean of 37.1 years.
Hence the age distribution in two groups did not match. Neither of the groups
were receiving any neuroleptic or other drugs which are well known to affect
dopamine metabolism in the brain.
Usually lumbar puncture was carried out between 9 and 10 A. M., and an
initial 5-6ml of CSF flowing out through the needle was collected for HVA
determination. The procedures were performed under ketamine anesthesia in
the patients under 7 years of age. TheCSF samples were placed immediately on
ice and then stored at -20°C until analysis. HVA was determined by the fluori-
metric method of Curzon et al. (11).
Statistical analysis was made using the Mann-Whitney V-test.
RESULTS
The results inTable 1 show an increase ofHVA concentration from fraction
I to III. The mean ratios of fractions II and III to fraction I were 1.46 (range
1.20-1.77) and 1.97 (range 1.33-3.01), respectively. This indicates an apparent
concentration gradient of HVA in the spinalCSF. However, the ratio between
fractions varied considerably in individual case. There was no correlation be-
tween the ratio and the clinical profiles of patients.
TABLE 1. CONCENTRATION OF HVA IN CSF IN FRACTIONS I-III
--- -- -_._-_._-~ ---_._------------._--_._----------------------
HVA (ng/ml)
Case Age Sex Clinical Diagnosis Fraction
II III
1 K. K. 3 F Epilepsy 63.2 76.0 (1. 20)" 95.2 (1.51)"
2 M.T. 4 F Epilepsy 36.0 58.3 (1. 62) 63.6 (1. 77)
3 A.G. 3 M Epilepsy 54.0 71. 7 (1. 33) 71. 7 (1. 33)
4 M.A. 10 M Epilepsy 21. 9 31. 5 (1. 44) 40.4 (1. 84)
5 N. N. 22 M Epilepsy 13.4 21. 7 (1.62) 40.4 (3.01)
6 I. O. 25 M Hyperventilation 25. 7 35. 1 (1. 37) 56.7 (2.21)
syndrome
7 M.M. F Hydroencephalo- 31. 5 40.8 (1. 30) 50.6 (1. 61)
dysplasia
8 A. F. 26 M Schizophrenia 23.9 29. 1 (1. 22) 63.6 (2.66)
9 S.M. 27 F Schizophrenia 28.9 51. 2 (1. 77) 59.0 (2.04)
10 S. K. 49 F Diencephalosis 26.5 45. 1 (1. 70)
11 T. K. 52 F Presenile dementia 27.1 45.7 (1. 69) 54.7 (2.02)
------
a The ratio of fraction II or III to fraction I is shown in parenthesis.
HVA concentrations in the lumbar CSF of the epileptic and control groups
are shown in Table 2. In the epileptic group HVA levels ranged from 4.5 to
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TABLE 2. CONCENTRATION OF HVA IN THE EPILEPTIC AND CONTROL PATIENTS
Concentration of HVA (ng/ml)
Epilepsy Control
Total 23.9 ± 2.8 (38)a 30. 2 ± 2. 1 (39)
Male 20.3 ± 3.6 (18) b 29.5 ± 2.8 (25)
Female 27.1 ± 4.2 (20)c 31. 4 ± 3. I (14)
Data given are mean values ± SEM with the number of cases in parenthesis.
a Different from control (p<0.005)
b Different from male control (p<O.005)
c Different from female control (p<O. 1)
68.4 ng/ml, with a mean value of 23.9 ng/ml± 2.8 SEM, which was significantly
reduced as compared with the control group ranging from 8.5 to 72.9 ng/ml,
with a mean value of 30.2 ng/ml±2.1 SEM. Although the mean HVA level in
the female patients was higher than in the male patients in both groups, this
difference was not statistically significant. As can be seen inFig. I, HVA levels
HVA (ng/ml)
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Fig. 1. The relationship between the HVA concentrations and the types of epi-
leptic seizures. Each point represents a specific patient. Dotted line represents the
mean concentration of controls.
in 20 (52.6%) cases out of 38 epileptic patients were below 20 ng/ml, while only
9 (23.1 %) cases of 39 control patients showed HVA levels less than 20 ng/ml.
There was no apparent correlation between the degree of reduced HVA concent-
ration and the type of seizures. HVA levels in five epileptic patients with no
antiepileptic medication (3 with generalized, one with psychomotor and one with
focal cortical seizures) were 14.4, 26.8, 30.5, 14.2 and 10.7 ng/ml, respectively.
There did not appear to be any consistent relationship between age and HVA
levels in both groups, as shown in Fig. 2. HVA levels were neither related to
seizure frequency nor antiepileptic medication.
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Fig. 2. The relationship between the HVA concentrations and the age of patients.
Each point represents a specific patient 1_, male epileptic; e, female epileptic; D,
male control; 0, female control).
DISCUSSION
Bernheimer et at. (12) and Barolin and Hornykiewicz (13) first reported
on the reduced HVA concentrations in the spinal CSF of epileptic patients. Re-
cently, Shaywitz et at. (14) suggested the possibility of reduced turnoverofdopa-
mine in the brain of children with epilepsy, since HVA concentrations in those
patients were significantly lower even after the administration of probenecid, a
drug that blocks the active transport of HVA from CSF (9). Papeschi et at. (15)
noted reduced HVA concentrations in the ventricular CSF of patients with
temporal lobe epilepsy. We also found low HVAconcentrations (139 ngjml±82
S. D.) in the ventricular CSF obtained during stereotaxic operation on 8 children
with intractable epilepsy (6 with Lennox-Gastaut syndrome and 2 with tonic-
clonic seizures) (16). Onthe other hand, however, Garelis and Sourkes (17) and
Fujii et at. (18) failed to find HVA differences between the epileptic and control
groups. Further, Chadwick et at. (19) found that HVA levels tended to be raised
in anticonvulsant-treated and well-controlled epileptic patients.
It is difficult to account for the~e conflicting results. Whereas an inhibitory
effect of phenobarbital on dopamtne metabolism has been reported (20), the
effect of anticonvulsants on HVA levels in CSF is currently unknown. Three
5
Kobayashi et al.: Homovanillic acid in human cerebrospinal fluid.--Its
Produced by The Berkeley Electronic Press, 1978298 K. KOBAYASHI et ai.
cases in the report ofShaywitz et al. (14) and 4of5 cases in this studyinvestigated
prior to initiating anticonvulsant medication had low concentrations ofHVA. In
addition, Shaywitz et al. (14) could not find any consistent relationship between
BVA concentrations in CSF and the blood levels of diphenylhydantoin or pheno-
barbital. From these results it is unlikely that the reduced BVA concentration
in CSF can be attributed to the effect of anticonvulsant medication.
Another possibility which could explain such a discrepancy might be that
epilepsy is a syndrome manifesting various types of epileptic seizures caused by
different etiologic factors or lesions at different sites in the brain. It should be
kept in mind that the subjects of the previous and present studies are epileptic
patients of different seizure types. It is not clear at the present time whether or
not all types of epileptic seizures are regulated by the same neurochemical me-
chanism. Although, in this study, we failed to find a significant relationship
between the degree of reduced BVA concentrations and the type of seizures,
further studies along this line are necessary to elucidate the relationship of re-
duced BVA concentration to epilepsy.
The relationship between brain monoamines and susceptibility to epileptic
seizures has been studied in experimental animals by a numberof investigators
(21,22). The results of these works suggest that the pharmacological treatments
lowering monoamine levels in the brain generally increase the susceptibility to
experimental seizures, while treatments that increase monoamines decrease the
susceptibility to seizures. At the present time, however, there is little agreement
as to which monoamine of the brain (dopamine, norepinephrine or serotonin) is
most intimately involved in seizure susceptibility. Of these monoamines, the
inhibitory action of dopamine to seizure susceptibility has been reported by
several authors (23-27). If dopamine plays an important role in regulating
seizure susceptibility even in the human brain, the decreased activity of dop-
aminergic neurons, suggested by the reduced HVA concentrations in the CSF,
must result in susceptibility to seizures in epileptic patients. As is well known,
however, the reduced BVA concentrations are not specific for epileptic patients.
It is necessary to clarify whether the decreased activity of dopaminergic neurons
relates directly or not to the seizure susceptibility of epileptic patients.
We have reported the first case in which L-DOPA, precursor of dopamine,
had a definite therapeutic effect on the psychomotor and adversive seizures (28).
The effect of L-DOPA on the epileptic patients with low levels of HVA was
reported recently by Cools et al. (29) and Sugie et at. (30).
A pronounced concentration gradient of BVA was found with a ratio of
1: 1.46: 1.97 between three fractions ofthe spinal CSF. A similar caudocranial
concentration gradient has been reported elsewhere (10, 17). The ratios obtained
in the present study are somewhat higher than those reported bySjostrom et al.
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(10). This might be due to mixing ofCSF in different compartments by air in-
jected during PEG. However, a significant gradient of HVA exists certainly
even in the spinal CSF. Therefore, it is necessary to standardize the conditions
for obtainingCSF in the clinical investigation on HVA levels of various neuro-
logical and psychiatric diseases.
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